Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Jan 9, 2022; 11(1): 48-57
Published online Jan 9, 2022. doi: 10.5492/wjccm.v11.i1.48
Published online Jan 9, 2022. doi: 10.5492/wjccm.v11.i1.48
Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease
Vijairam Selvaraj, Arkadiy Finn, Muhammad Baig, Atin Jindal, Kwame Dapaah-Afriyie, Department of Medicine, Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI 02906, United States
Amos Lal, Department of Medicine, Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN 55905, United States
Joshua Ray Tanzer, Department of Biostatistics Core, Lifespan Group, Providence, RI 02906, United States
George Bayliss, Department of Medicine, Rhode Island Hospital and Alpert Medical School, Bayliss, Division of Kidney and Hypertension, Brown University, Providence, RI 02906, United States
Author contributions: Selvaraj V, Finn A and Lal A were responsible for the conception and design of the work, screening of papers and drafting the manuscript; Jindal A was responsible for the literature review and contributed to manuscript writing; Tanzer JR and Baig M performed analysis and final approval; Jindal A, Dapaah-Afriyie K and Bayliss G contributed to research oversight, data review and manuscript revision.
Institutional review board statement: Institutional review board statement: This study was reviewed and approved by the IRB of the Miriam Hospital. IRB # 20-054
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Noncommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amos Lal, FACP, MBBS, Assistant Professor, Department of Medicine, Division of Pulmonary and Critical Care, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States. manavamos@gmail.com
Received: June 2, 2021
Peer-review started: June 2, 2021
First decision: July 31, 2021
Revised: August 4, 2021
Accepted: December 23, 2021
Article in press: Deccember 23, 2021
Published online: January 9, 2022
Processing time: 216 Days and 7.4 Hours
Peer-review started: June 2, 2021
First decision: July 31, 2021
Revised: August 4, 2021
Accepted: December 23, 2021
Article in press: Deccember 23, 2021
Published online: January 9, 2022
Processing time: 216 Days and 7.4 Hours
Core Tip
Core Tip: Little known information exists regarding the efficacy of remdesivir in corona virus disease 2019 patients with end stage renal disease on dialysis. Use of remdesivir was associated with a trend towards reduced oxygen requirement, reduced probability of progression to mechanical ventilation and better prognosis. Larger studies are justified in this high risk, vulnerable population.